QNCX
Quince Therapeutics, Inc.
Quince Therapeutics, Inc. (QNCX) is currently in a downtrend, trading below both the 50-day and 200-day moving averages. RSI is at 48.0, with 0/3 trend checks passing.
QNCX with MA50 and MA200
Key levels & signals
Quince Therapeutics, Inc. (QNCX) currently looks weaker on the chart and is not showing much trend strength. The latest available price is $18.58, and 0 of 3 core trend checks are currently passing. Price is trading below the 50-day moving average by 9.7% and below the 200-day moving average by 92.1%.
QNCX currently has an RSI reading of 48.0, which sits in a neutral range. That usually means momentum is not especially stretched in either direction, so traders may need to rely more on chart structure than on oscillator extremes alone.
For traders reviewing QNCX next, the main question is whether weakness is starting to stabilise or whether the chart still looks vulnerable to further downside. Some traders may watch for bounce attempts, but others will want to see stronger proof that the trend is improving before treating the stock as a cleaner setup.
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.
Learn the indicators behind this page
More stock opportunities
Common questions about QNCX
Is this page a buy or sell recommendation?
No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.
Why can a stock look bullish and overbought at the same time?
Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.
What should I do next after reading this page?
Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.